A Phase II Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Rigosertib (Primary)
- Indications Anaemia; Myelofibrosis
- Focus Therapeutic Use
- 17 Aug 2017 Planned End Date changed from 1 Sep 2022 to 1 Aug 2022.
- 17 Aug 2017 Planned primary completion date changed from 1 Sep 2022 to 1 Aug 2022.
- 17 Aug 2017 Status changed from not yet recruiting to recruiting.